Gilead Sciences Statement on Positive Data Emerging From National Institute of Allergy and Infectious Diseases? Study of Investigational Antiviral Remdesivir for COVID-19

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences. Inc. (Nasdaq: GILD) is aware of positive data emerging from the National Institute of Allergy and Infectious Diseases? (NIAID) study of the investigational antiviral remdesivir for the treatment of COVID-19. We understand that the trial has met its primary endpoint and that NIAID will provide detailed information at an upcoming briefing. Remdesivir is not yet licensed or approved anywhere globally and has not yet been demonstrated to be saf

Click to view original post